• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

bivacor

BiVacor wins FDA breakthrough nod for Total Artificial Heart

May 30, 2025 By Sean Whooley

BiVacor announced today that it received FDA breakthrough device designation for its Total Artificial Heart (TAH) system. The designation supports the TAH as a bridge to transplant (BTT) for adults with severe biventricular or univentricular heart failure where current treatments, including LVADs, are not viable. “This is more than a regulatory milestone. It’s a validation […]

Filed Under: Cardiac Implants, Cardiovascular, Featured, Food & Drug Administration (FDA), Implants, Regulatory/Compliance, Replacement Heart Valves, Structural Heart Tagged With: bivacor, FDA

FDA greenlights expansion of BiVacor artificial heart study

December 18, 2024 By Sean Whooley

BiVacor announced today that it completed the first phase of an FDA early feasibility study (EFS) for its Total Artificial Heart (TAH). Five patients received the BiVacor TAH between July and November 2024 in the study looking at the TAH as a bridge to donor heart transplant. The initial phase supported patients with the TAH […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Food & Drug Administration (FDA), Implants, Regulatory/Compliance, Structural Heart, Transplants Tagged With: bivacor, FDA

BiVacor reports first human implant of artificial heart

July 30, 2024 By Sean Whooley

BiVacor recently announced the successful first-in-human implantation of its Total Artificial Heart (TAH) as part of an early feasibility study. Surgeons at Baylor St. Luke’s Medical Center in the Texas Medical Center completed the procedure on July 9. The first-in-human clinical study utilizing the TAH aims to evaluate the safety and performance of the system […]

Filed Under: Cardiac Implants, Cardiovascular, Featured, Implants, Replacement Heart Valves, Structural Heart Tagged With: bivacor

BiVacor raises $13M to support artificial heart trial

February 20, 2024 By Sean Whooley

BiVacor announced today that it brought in $13 million from the Australian government to support its Total Artificial Heart program. Australia’s Medical Research Future Fund (MRFF) provided a grant through its Artificial Heart Frontiers Program (AHFP). It aims to support the company’s TAH program and future product enhancements. BiVacor received FDA investigational device exemption to […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Funding Roundup, Replacement Heart Valves, Structural Heart Tagged With: bivacor

BiVacor picks former BioVentrix CEO for its corner office

January 3, 2024 By Sean Whooley

Artificial heart maker BiVacor announced today that it appointed Jim Dillon as its new CEO and as a member of its board. Dillon, an experienced medical device executive, most recently served as CEO of BioVentrix, a heart failure treatment developer. His appointment follows last week’s naming of Axonics CEO Raymond W. Cohen as board chair […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Replacement Heart Valves, Structural Heart Tagged With: bivacor, Personnel Moves

Artificial heart maker BiVacor names Axonics CEO as chair of its board

December 27, 2023 By Sean Whooley

BiVacor announced today that it appointed Axonics CEO Raymond W. Cohen as the new chair of its board of directors. Cohen serves as CEO and as a member of the board at Axonics, which develops sacral neuromodulation technologies. He originally founded Axonics in 2013 and took the Irvine, California-based company public in October 2018. The long-time […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Featured, Replacement Heart Valves, Structural Heart Tagged With: Axonics, bivacor, Personnel Moves

BiVacor wins FDA IDE for first-in-human artificial heart study

November 29, 2023 By Sean Whooley

BiVacor announced today that the FDA granted investigational device exemption (IDE) for its total artificial heart (BTAH). IDE approval allows BiVacor to begin its first-in-human early feasibility study (EFS) for the BTAH system. The Houston-based company aims to evaluate BTAH’s safety and feasibility as a bridge to a heart transplant for patients with biventricular heart […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Featured, Food & Drug Administration (FDA), Implants, News Well, Regulatory/Compliance, Replacement Heart Valves, Structural Heart Tagged With: artificial hearts, bivacor, FDA

BiVacor looks to implant its artificial heart in a person next year

March 30, 2023 By Chris Newmarker

BiVacor has raised $18 million to support the continued development of its preclinical artificial heart device. Cormorant Asset Management and OneVentures, through the OneVentures Healthcare Fund III, led the funding round, according to a March 29 news release from Houston-based BiVacor. The investments will fund the company’s continued research and development and early feasibility first […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Featured, Funding Roundup, News Well, Structural Heart Tagged With: artificial hearts, bivacor

Artificial heart developer BiVacor taps former Abiomed exec as CEO

January 14, 2022 By Danielle Kirsh

BiVacor this week announced that former Abiomed executive Thomas Vassiliades was appointed CEO, effective immediately. Prior to joining the company, Vassiliades was most recently the general manager of the surgery and heart failure business at Abiomed. He has also served as the chief medical officer of the coronary and structural heart business of Medtronic, and […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, News Well, Structural Heart Tagged With: Abiomed, bivacor, Medtronic

What should the Mann Foundation do next?

December 31, 2018 By Nancy Crotti

Dr. Robert Greenberg, the Mann Foundation’s new executive chairman, has ideas about where to take one of medtech’s top research and development outfits. He explained more at DeviceTalks West in December. The new executive chairman of the Alfred E. Mann Foundation for Scientific Research sees the foundation continuing its mission of developing devices for unmet medical needs. The foundation […]

Filed Under: Bioelectronic Medicine, Clinical Trials, Implants, Neuromodulation/Neurostimulation, News Well, Orthopedics, Prosthetics, Research & Development, Vision Tagged With: Advanced Bionics LLC, Alfred E. Mann Foundation, Axonics Modulation Technologies, bivacor, DeviceTalks West, Johns Hopkins University, Medtronic, Second Sight, stjudemedical, walterreednationalmilitarymedicalcenter

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy